Posted 9/24/2016 10:58 PM (GMT 0)
So, if I understand you, he is on active surveillance now, and his next biopsy (within a year) will be a transperineal template mapping (saturation) biopsy. It won't really tell you if the cancer has spread very much. Prostate cancer does not spread that quickly that a follow-up biopsy can detect whether it's really spread. And the first biopsy was just a small sampling of the prostate tissue. What it tells you is if any significant cancer was missed on the first 12-core TRUS biopsy. about 30% of Gleason 6 cancers are found to be a higher grade when men have a prostatectomy and they are able to inspect the whole thing. So these follow-up biopsies confirm that his type of prostate cancer is safe to monitor and not treat. Over the years, he will get a better idea if his type of prostate cancer is the kind that stays indolent (about half remain indolent).
It's a good idea to have Epstein's lab at Johns Hopkins give a second opinion on the biopsy slides.
Saturation biopsies are the gold standard. Some guys have an multiparametric MRI-targeted biopsy on the follow-up biopsy. It only detects higher grade cancer, and they don't have to take as many cores. They can do both too.